Job Description
The Associate Director, Market Access, Biosimilars will report to the Director of Strategic Pricing and Contracting and be responsible for the development of the US launch pricing and contracting strategy for the US Biosimilars Business Unit, with an initial focus in Ophthalmology.
Specifically, s/he will be responsible for the strategic approach to biosimilar pricing and delivering recommended contracting strategy by customer segment. This includes but is not limited to identifying potential innovative contracting frameworks (e.g., outcomes/value-based contracting); developing the post-launch contracting strategy plan; and building pricing proposals, business cases (in collaboration with Finance), and internal pricing communications. The individual will work closely with the US Contracting Operations team to ensure contracting and pricing strategy is aligned with field implementation and pull-through. Working with the Health Policy team to apply anticipated policy changes related to biosimilars into future contracting scenario planning will be critical.
This individual will be required to work cross-functionally to achieve the business objectives described above and ensure organizational alignment and approvals. The individual will partner with the Payer Channel Marketing and the Payer Insights teams to align payer value proposition, collect key customer insights, and analyze market in terms of coverage and reimbursement, payer policies, formulary listings, and barriers to patient access. Work with cross-functional teams (Contracting Operations, Field Marketing, etc.) will be required to support training and educating account managers on contracting strategies. Collaboration with the Health Policy and Government Affairs team to integrate anticipated policy changes into future approaches towards contracting with government and private payers is important.
Responsibilities:
Lead the execution of pricing and contracting strategies for Biogens biosimilar products
Understand channel dynamics and impact on stakeholders to identify opportunities, risks and develop subsequent strategies for implementation
Build innovative contracting frameworks for biosimilars to maximize payer access, including value-based agreements
Collaborate with the Payer Insights and Payer Channel Marketing team to understand the impact of changes in the competitive landscape on contracting strategies
Work with US Health Policy team to anticipate policy changes and develop relevant contracting scenarios
Partner with Public Policy Government Affairs to understand policy environment and implications
Work with Commercial and Finance/Forecasting teams to develop the business case for pricing and contracting recommendations to US and Global leadership teams for approval
Serve as a content expert to ensure that the pricing and contracting perspective is taken into account in cross-functional work streams
Independently manage projects from start to finish
*LI-SR6
Qualifications
Graduate level degree (Masters or higher) and at least 5 years prior experience in the biopharmaceutical industry is required
Strong understanding of buy-and-bill mechanics, physician contracting, and ASP dynamics for Medicare Part B products
Experience with specialty pharmacy products across pharmacy and/or medical channels is required
Knowledge of US government pricing dynamics (Medicaid, 340B, Medicare Parts B and D)
Experience with financial/forecasting models within market access and pricing role
Excellent analytical, strategic thinking and critical thinking skills
Ability to develop and deliver clear, compelling presentations on complex pricing topics to senior-level executive audience
Must be highly motivated with strong interpersonal and communications skill
Ability to handle multiple tasks and effectively prioritize to meet individual and team goals
Must be able to work independently and produce high quality, accurate work within allocated timelines
Ability to build and maintain strong cross-functional and cross-team ties to influence colleagues
Must have the ability to work effectively within a cross-functional team
Additional Information
The Associate Director, Market Access, Biosimilars will report to the Director of Strategic Pricing and Contracting and be responsible for the development of the US launch pricing and contracting strategy for the US Biosimilars Business Unit, with an initial focus in Ophthalmology.
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.